3 recruiting. 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 3 | Recruiting 3 |
Follow Adjuvant Therapy: new trials by email Literature Review of Adjuvant Therapy trials Research Report on Adjuvant Therapy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Adjuvant Immune Checkpoint Inhibitor Versus Observation After Neoadjuvant Immunochemotherapy and Surgery in High-Risk NSCLC Sintilimab - Non-Small Cell Lung Cancer, Adjuvant Therapy | Phase 2 | Recruiting | Sichuan University | 100 | 2025-01-10 | 2026-08-05 |
| Perioperative Tislelizumab Plus Chemotherapy for Resectable Thoracic Oesophageal Squamous Cell Carcinoma Tislelizumab - Esophageal Squamous Cell Carcinoma, Neoadjuvant Chemoimmunotherapy | Phase 2 | Recruiting | Guo Xufeng | 73 | 2023-09-07 | 2023-09-28 |
| Compare Continuation of Original Targeted Therapy With Trastuzumab Combined With Pyrotinib and Capecitabine as Postoperative Adjuvant Therapy in Non-pCR Patients With HER2 Positive Early Breast Cancer Pyrotinib+Trastuzumab+Capecitabine, Trastuzumab+Pertuzumab/Trastuzumab - Breast Cancer, Adjuvant Therapy | Phase 2 | Recruiting | Fujian Medical University Union Hospital | 206 | 2021-07-02 | 2022-03-23 |
Breast Neoplasms (1) · Carcinoma, Non-Small-Cell Lung (1) · Esophageal Squamous Cell Carcinoma (1)
Neoplasms (3) · Neoplasms by Site (3) · Breast Diseases (1) · Bronchial Neoplasms (1) · Carcinoma (1) · Carcinoma, Bronchogenic (1) · Carcinoma, Squamous Cell (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Esophageal Diseases (1) · Esophageal Neoplasms (1) · Gastrointestinal Diseases (1) · Gastrointestinal Neoplasms (1) · Head and Neck Neoplasms (1) · Lung Diseases (1)
Albumin-Bound Paclitaxel (1) · Carboplatin (1) · Trastuzumab (1) · sintilimab (1) · tislelizumab (1)
Fujian Medical University Union Hospital (1) · Guo Xufeng (1) · Sichuan University (1)
China (3)
Changqing Pan (1)